Advertisement

Index by author

April 01, 2023; Volume 51,Issue 4

  1. Amilon, Carl

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100
    2. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  2. Amory, John K.

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  3. Andersson, Linda C.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  4. Antonsson, Thomas

    1. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Open Access
      Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans
      Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 464-479; DOI: https://doi.org/10.1124/dmd.122.001099

  5. Basit, Abdul

    1. Relevance of Human Aldoketoreductases and Microbial β-Glucuronidases in Testosterone Disposition
      Abdul Basit, John K. Amory, Vijaya Saradhi Mettu, Cindy Yanfei Li, Scott Heyward, Parth B. Jariwala, Matthew R. Redinbo and Bhagwat Prasad
      Drug Metabolism and Disposition April 2023, 51 (4) 427-435; DOI: https://doi.org/10.1124/dmd.122.000975

  6. Bhattacharya, Chandrali

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  7. Bragg, Ryan A.

    1. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Open Access
      Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans
      Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf and V. Sashi Gopaul
      Drug Metabolism and Disposition April 2023, 51 (4) 451-463; DOI: https://doi.org/10.1124/dmd.122.001100

  8. Bumpus, Namandjé N.

    1. Open Access
      Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems
      Abigail M. Wheeler, Benjamin C. Orsburn and Namandjé N. Bumpus
      Drug Metabolism and Disposition April 2023, 51 (4) 521-531; DOI: https://doi.org/10.1124/dmd.122.001195

  9. Chang, Qi

    1. CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
      Weihong Yang, Huan Zhao, Yaojie Dou, Pei Wang, Qi Chang, Xiaomeng Qiao, Xiaofei Wang, Chen Xu, Zhe Zhang and Lirong Zhang
      Drug Metabolism and Disposition April 2023, 51 (4) 492-498; DOI: https://doi.org/10.1124/dmd.122.001111

  10. Cho, Sungjoon

    1. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
      Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware and Laurent Salphati
      Drug Metabolism and Disposition April 2023, 51 (4) 436-450; DOI: https://doi.org/10.1124/dmd.122.001096
« Previous (Pages : 1 2 3 4 5 6 ... 9) Next »
Back to top

In this issue

Advertisement